FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss
SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)-- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy (IgAN), Kidney Disease: Improving Global Outcomes (KDIGO) 2025 clinical practice guideline for the management of IgA Nephropathy and Immunoglobulin A vasculitis. The updated guidelines define diagnostic criteria, treatment goals and treatment approaches, aiming for progress for people living with IgAN and the clinicians who treat them.
The 2025 update defines remission of proteinuria (